Conferences - Results from #9880

AUA 2017:Non-Muscle Invasive Bladder Cancer Guidelines May 16, 2017

AUA 2017: High Risk Non-Muscle Invasive Bladder Cancer May 16, 2017

AUA 2017: What is Best Systemic Therapy for Metastatic/Invasive Bladder Cancer? May 16, 2017

AUA 2017: What is the Best Imaging and What Will We Be Using in the Future: Cystoscopy and Cross-Sectional Imaging? May 16, 2017

AUA 2017: Beyond Cytology: What is the Urinary Marker We Should Use Now and What Will Be the Best in the Future? May 16, 2017

AUA 2017: Best Urothelial Cancer papers from 2016 May 16, 2017

AUA 2017: How I Screen - Panel May 16, 2017

AUA 2017: Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): final results and translational findings of an open-label, single-arm, phase 2 study May 16, 2017

AUA 2017: Development and external validation of a novel 12-gene signature on muscle-invasive bladder cancer for prediction of overall survival: linkage to data from The Cancer Genome Atlas May 16, 2017

AUA 2017: Molecular subtypes of muscle invasive bladder cancer are related to benefit from neoadjuvant chemotherapy May 16, 2017

AUA 2017: Genome Drivers of Response to Existing and Emerging Therapies in Bladder Cancer May 16, 2017

AUA 2017: Creating an Institution-Wide Systems Biology Initiative May 16, 2017

AUA 2017: Studying Niche Populations: Neuroendocrine Prostate Cancers May 16, 2017

AUA 2017: Leveraging the Power of Ultra-Deep Sequencing (When Deep Sequencing Fails) May 16, 2017

AUA 2017: Opportunities and Challenges Associated with Big Data May 16, 2017

AUA 2017: Prospective Study Of Biopsy Decipher Scores In Potential Candidates For Active Surveillance May 16, 2017

AUA 2017: Multiparametric-MRI Prior To Repeat Biopsy For Active Surveillance Can Identify Men With High-risk Prostate Cancer May 16, 2017

AUA 2017: Concordance Between Physician-documented Versus Patient-reported Comorbidities In Prostate Cancer: Validation Of A Novel Informatics Tool May 16, 2017

AUA 2017: Worldwide Variation In Determinants For Inclusion And Follow-up In Active Surveillance For Low-risk Prostate Cancer: Results Of The Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative May 16, 2017

AUA 2017: Association Between Germline Genetic Variation And Progression In Men With Low-risk Prostate Cancer On Active Surveillance May 16, 2017

Page 495 of 614